TriOar is a biotech company focusing on developing next-generation antibody-based therapeutics with novel platform technologies.

2023
10

Won Seoul-BMS Innovation² Challenge 2023

07

Selected for “Baby Unicorn Startups 200” by KISED

Selected for KFDA grant with Chungnam Univ. (ADC)

06

Filed 2 OAR3 PCT Applications

05

Raised Series A Funding (12 billion KrW)

2022
12

Filed OAR2 Patent Application, Korea

10

Filed OAR1 Patent Application, Korea

06

Filed 2 OAR3 Patent Applications, Korea

03

Selected for Government Support Program
(Ministry of SMEs and Startups)

01

Raised Pre-series A Funding (5 billion KrW)

2021
11

Announced Research Collaboration with Cbiomex

07

Announced Research Collaboration with Y-Biologics

05

Acquired Venture Enterprise Certification

Raised Angel Funding (1.95 billion KrW)

Selected for Government Support Program
(Ministry of SMEs and Startups)

03

Acquired Corporate Research Center Certification

01

Founded